On July 9, 2025, Moleculin Biotech, Inc. announced that its Clinical Trial Application for the drug Annamycin, to treat acute myeloid leukemia, was approved in Georgia. This pivotal Phase 2B/3 study will explore the combination of Annamycin with cytarabine for patients who are resistant or have relapsed from previous treatments.